A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases.
William J Phillips, Tabassom Baghai, Michael Ong...
https://pubmed.ncbi.nlm.nih.gov/33450821/Actively Recruiting
Led by Melanoma Institute Australia · Updated on 2026-10-08
218
Participants Needed
9
Research Sites
139 weeks
Total Duration
Researchers are evaluating the combination of immunotherapy drugs ipilimumab and nivolumab with or without concurrent stereotactic radiotherapy in patients who have asymptomatic, untreated melanoma brain metastases. This phase II randomized trial aims to compare these treatments to determine their effect on neurological death rate at 12 months and assess other outcomes such as tumor response, progression-free survival, overall survival, neurocognitive function, adverse events, and quality of life. The study builds on previous findings that combining these immunotherapies is more effective than nivolumab alone and investigates how radiotherapy might boost immune responses against tumors. Participants will receive ipilimumab and nivolumab at doses approved for advanced melanoma. One group will also receive stereotactic radiotherapy to brain metastases within seven days of a baseline MRI scan. Radiotherapy doses vary by lesion size and are delivered in one or several fractions. Both groups may receive salvage therapies like surgery or radiotherapy if brain disease progresses. Treatment is administered according to a 11 randomization with stratification by factors such as brain metastases count and mutation status. During participation, patients will undergo regular MRIs, neurocognitive tests using the Montreal Cognitive Assessment, neurological exams with the NANO scale, and quality of life questionnaires including FACT-Brain and EORTC modules. Blood, tissue, stool, and urine samples will be collected for biomarker analysis. Adverse events will be monitored closely, and continued treatment beyond progression may be allowed if clinically appropriate. The study plans long-term follow-up up to 10 years to track outcomes and safety, with total participation lasting up to the study completion in 2029.
CONDITIONS
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
G
Georgina V Long, MBBS PhD
M
Maria Gonzalez, RN MHSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Melanoma Institute Australia
Lead Sponsor
Bristol-Myers Squibb
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are evaluated for eligibility including medical history, imaging, and laboratory tests.
1 to 2 visits
Duration - Up to 2 years or until disease progression
Participants receive ipilimumab and nivolumab immunotherapy; one group also receives stereotactic radiotherapy to brain metastases shortly after a baseline MRI. Salvage therapies may be used if disease progresses.
Regular visits every 3 to 4 weeks for drug administration and assessments
Duration - Up to 10 years
Participants are monitored with imaging, neurocognitive tests, quality of life assessments, and biomarker sampling to evaluate outcomes and safety up to 10 years.
Periodic visits every 6 to 12 weeks initially, then less frequently over time
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
William J Phillips, Tabassom Baghai, Michael Ong...
https://pubmed.ncbi.nlm.nih.gov/33450821/Melanoma Institute Australia
Lead Sponsor
Bristol-Myers Squibb
Collaborating Sponsor